Sumitomo Life Insurance Co. raised its stake in HCA Healthcare Inc (NYSE:HCA) by 6.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 18,920 shares of the company’s stock after purchasing an additional 1,064 shares during the quarter. Sumitomo Life Insurance Co.’s holdings in HCA Healthcare were worth $2,797,000 at the end of the most recent reporting period.
A number of other hedge funds also recently bought and sold shares of HCA. Assenagon Asset Management S.A. grew its stake in HCA Healthcare by 7,356.0% in the fourth quarter. Assenagon Asset Management S.A. now owns 710,105 shares of the company’s stock valued at $104,961,000 after purchasing an additional 700,581 shares in the last quarter. Redmile Group LLC bought a new position in HCA Healthcare in the third quarter valued at approximately $28,359,000. Nomura Holdings Inc. bought a new position in HCA Healthcare in the second quarter valued at approximately $29,442,000. State of New Jersey Common Pension Fund D bought a new position in HCA Healthcare in the third quarter valued at approximately $25,854,000. Finally, Squarepoint Ops LLC bought a new position in HCA Healthcare in the third quarter valued at approximately $19,484,000. Hedge funds and other institutional investors own 69.33% of the company’s stock.
A number of research analysts have weighed in on the company. Deutsche Bank assumed coverage on HCA Healthcare in a research note on Friday, January 3rd. They issued a “buy” rating and a $140.00 price target for the company. ValuEngine upgraded HCA Healthcare from a “sell” rating to a “hold” rating in a research note on Wednesday, October 2nd. Bank of America raised HCA Healthcare from a “neutral” rating to a “buy” rating in a research report on Friday, December 6th. Barclays raised their price objective on HCA Healthcare from $145.00 to $155.00 and gave the company an “overweight” rating in a research report on Wednesday, October 30th. Finally, JPMorgan Chase & Co. raised their price objective on HCA Healthcare from $157.00 to $186.00 and gave the company an “overweight” rating in a research report on Friday, December 20th. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. HCA Healthcare presently has an average rating of “Buy” and an average target price of $156.07.
HCA Healthcare (NYSE:HCA) last released its quarterly earnings results on Tuesday, October 29th. The company reported $2.23 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.13 by $0.10. The business had revenue of $12.69 billion during the quarter, compared to analysts’ expectations of $12.48 billion. HCA Healthcare had a negative return on equity of 173.49% and a net margin of 6.98%. The firm’s revenue for the quarter was up 10.9% compared to the same quarter last year. During the same period last year, the firm posted $2.16 EPS. As a group, research analysts predict that HCA Healthcare Inc will post 10.53 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Friday, December 27th. Investors of record on Monday, December 2nd were issued a dividend of $0.40 per share. The ex-dividend date was Friday, November 29th. This represents a $1.60 annualized dividend and a yield of 1.12%. HCA Healthcare’s payout ratio is currently 16.38%.
In related news, insider Michael S. Cuffe sold 5,891 shares of HCA Healthcare stock in a transaction that occurred on Monday, December 23rd. The stock was sold at an average price of $147.04, for a total transaction of $866,212.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Jon M. Foster sold 19,477 shares of HCA Healthcare stock in a transaction that occurred on Thursday, October 31st. The stock was sold at an average price of $132.35, for a total value of $2,577,780.95. Following the sale, the insider now directly owns 10,015 shares of the company’s stock, valued at $1,325,485.25. The disclosure for this sale can be found here. Over the last three months, insiders have sold 48,511 shares of company stock valued at $6,592,095. 2.70% of the stock is currently owned by insiders.
HCA Healthcare Profile
HCA Healthcare, Inc, through its subsidiaries, provides health care services. The company operates general, acute care hospitals that offer medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy services.
Recommended Story: What is a balanced fund?
Receive News & Ratings for HCA Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCA Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.